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Purpose: To evaluate whether the risk of prostate cancer was different according to the pattern of fluctuation in prostate-specific 
antigen (PSA) levels in patients undergoing repeat transrectal ultrasound-guided prostate biopsy (TRUS-Bx).
Methods: From March 2003 to December 2012, 492 patients underwent repeat TRUS-Bx. The patients were stratified into 3 groups 
based on the PSA fluctuation pattern: group 1 (continuous elevation of PSA, n =169), group 2 (PSA fluctuation with PSA velocity 
[PSAV]≥1.0 ng/mL/yr, n=123), and group 3 (PSA fluctuation with PSAV<1.0 ng/mL/yr, n=200).
Results: Prostate cancer was detected in 112 of 492 patients (22.8%) in the repeat biopsy set. According to the PSA fluctuation 
pattern, prostate cancer detection rates at repeat TRUS-Bx were 29.6% (50/169) for patients with continuously increasing PSA, 30.1% 
(37/123) for PSA fluctuation with PSAV ≥1.0 ng/mL/yr, and 12.5% (25/200) for PSA fluctuation with PSAV <1.0 ng/mL/yr. Multivariate 
analysis showed that PSA fluctuation pattern and high grade prostatic intraepithelial neoplasia at initial TRUS-Bx were the predictive 
parameters for positive repeat biopsies. Among the 96 patients (85.7%) who underwent radical prostatectomy, no significant 
differences in pathologic outcomes were found according to the PSA fluctuation pattern.
Conclusions: The current study shows that the risk of prostate cancer at repeat TRUS-Bx was higher in men with a fluctuating PSA 
level and PSAV≥1.0 ng/mL/yr than in those with a fluctuating PSA level and PSAV<1.0 ng/mL/yr.
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INTRODUCTION
Transrectal ultrasound-guided prostate biopsy (TRUS-Bx) is 
the most effective method for diagnosis of prostate cancer; 
however, TRUS-Bx may underestimate the presence of cancer. 
Therefore, repeat biopsy must be considered in patients with 
persistent diagnostic doubts after an initial negative biopsy. 
In the Medicare population, the risk of repeat biopsy in men 
with a negative first biopsy was 11.6% at 1 year and 38.0% at 
5 years [1]. Although TRUS-Bx is generally considered safe, 
many urologists have experienced a conflict between the risk 
of prostate cancer and biopsy-related morbidity that includes 
rectal bleeding and infectious complications [2-5]. Because of 
the aforementioned concerns, the use of alternative biomark-
ers or predicting factors has become mandatory in predicting 
the presence of prostate cancer in cases where clinically sus-
pected cancer is not supported by initial histologic findings.
 Prostate-specific antigen (PSA) is the universally accepted 
tumor marker for diagnosis of prostate cancer. Many urolo-
gists frequently encounter patients with fluctuating PSA levels 
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rejected if P-values were less than 0.05.
RESULTS
The baseline characteristics of the cohort are presented in 
Table 1. The mean age of the patients was 65.2 years; their 
mean PSA levels before the initial and repeat biopsy sets were 
8.2 and 9.9 ng/mL, respectively (P = 0.016). Only 11 of the 
492 patients (2.2%) experienced adverse events after repeat 
TRUS-Bx, with acute prostatitis in 7 patients, rectal bleeding 
in 3 patients, and acute urinary retention in 1 patient.
 Prostate cancer was detected in 112 of 492 patients (22.8%) 
in the repeat biopsy set; 6 of 40 patients (15.0%) in the third 
biopsy set; and 1 of 4 patients (25.0%) in the fourth biopsy 
set. According to the PSA fluctuation pattern, prostate cancer 
detection rates at repeat TRUS-Bx were 29.6% (50/169) for 
patients with continuously increasing PSA, 30.1% (37/123) for 
PSA fluctuation with PSAV≥1.0 ng/mL/yr, and 12.5% (25/200) 
for PSA fluctuation with PSAV < 1.0 ng/mL/yr. 
 There was no statistical significance between patients with 
and without prostate cancer at repeat TRUS-Bx for age (66.8 
years vs. 64.7 years, P = 0.089), body mass index (23.6 kg/m2 
vs. 23.7 kg/m2, P = 0.867), and prostate volume (46.3 mL vs. 
49.4 mL, P = 0.249). Patients with prostate cancer had higher 
PSA levels at repeat TRUS-Bx (10.2 ng/mL vs. 9.1 ng/mL, P =  
0.012), higher PSA density (0.21 ng/mL/mL vs. 0.14 ng/mL/
mL, P = 0.041), and higher PSAV (1.23 ng/mL/yr vs. 0.91 ng/
mL/yr, P < 0.001). Multivariate analysis showed that PSA fluc-
tuation pattern and HGPIN at initial TRUS-Bx were the pre-
dictive parameters for positive biopsies (Table 2).
 Ninety-six patients (85.7%) underwent radical prostatec-
tomy. Table 3 presents the pathologic results of the surgical 
specimen. Pathologic stage was organ confined in 90.6% of 
after initial TRUS-Bx. Traditionally, these patients were con-
sidered as having a lower risk of prostate cancer than patients 
with steadily increasing PSA levels; however, there is paucity 
of firm evidence for this hypothesis [6,7].
 The aim of the current study was to evaluate whether the 
risk of prostate cancer was different according to the PSA 
fluctuation pattern in patients undergoing repeat TRUS-Bx 
for suspected prostate cancer.
 
MATERIALS AND METHODS
From March 2003 to December 2012, 5,828 consecutive men 
with a mean age of 64.8 (±9.3) years underwent TRUS-Bx with 
a mean of 12.6 ( ± 1.3) biopsy cores. The indication for initial 
TRUS-Bx was either an elevated PSA level ( ≥ 3 ng/mL) or ab-
normal digital rectal examination (DRE). Prostate cancer was 
detected in 2,047 men (35.1%) at initial TRUS-Bx. Of the 3,781 
patients whose biopsy result was negative, 492 underwent re-
peat TRUS-Bx because of the high risk of prostate cancer with 
prior high-grade prostatic intraepithelial neoplasia (HGPIN) 
or atypical small acinar proliferation of prostate, persistently 
elevated PSA, or increase in PSA level during follow-up. In 
all patients, the prostate was routinely biopsied bilaterally 
near the base, midgland, and apex with at least six biopsies 
per side. All biopsy cores were reviewed by a single board-
certified uropathologist (K.Y.C.) using contemporary diagnos-
tic criteria. In the presence of prostate cancer, either radical 
prostatectomy or radiation therapy was recommended.
 After approval by the Institutional Review Board at Seoul 
National University Bundang Hospital (B-1310-222-109), 
clinical and pathologic data, including patient age, PSA, PSA 
density, PSA velocity (PSAV), and PSA fluctuation pattern were 
analyzed using our computerized database. PSAV was calcu-
lated as PSA level at the time of second biopsy minus PSA level 
at the time of first biopsy divided by the time elapsed in years 
between two measurements. PSA fluctuation was defined as a 
PSA series with at least one PSA value lower than the one im-
mediately preceding it. The patients were stratified into three 
groups based on the PSA fluctuation pattern: group 1 (continu-
ous elevation of PSA, n =169), group 2 (PSA fluctuation with 
PSAV ≥1.0 ng/mL/yr, n =123), and group 3 (PSA fluctuation 
with PSAV<1.0 ng/mL/yr, n=200).
 All statistical analysis was performed using IBM SPSS ver. 
19.0 (IBM Co., Armonk, NY, USA). Demographics and clini-
cal parameters were analyzed with the chi-square test for 
categorical variables and the one-way analysis of variance 
test or the Kruskal-Wallis test, as appropriate for continuous 
variables. Two-sided null hypotheses of no difference were 
Table 1. Baseline patient characteristics
Characteristic Value
Age (yr) 65.2±7.8
Body mass index (kg/m2) 23.7±4.8
PSA at initial biopsy (ng/mL) 8.2±0.3
PSA at repeated biopsy (ng/mL) 9.9±0.4
Prostate volume (mL) 48.8±21.1
Transition zone volume (mL) 25.7±17.6
PSA density (ng/mL/mL) 0.16±0.09
PSA velocity (ng/mL/yr) 1.05±1.90
Abnormal DRE 48 (9.8)
Abnormal TRUS 73 (14.8)
Months interbiopsy interval 16.0±12.1
Values are presented as mean±standard deviation or number (%).
PSA, prostate-specific antigen; DRE, digital rectal examination; TRUS, 
transrectal ultrasound.
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lowing biopsies) [1]. According to the different techniques 
used for prostate biopsy, cancer detection rates in repeat satu-
ration prostate biopsy range from 13.7% to 45.0% [8-11]. Use 
of an extended prostate biopsy protocol with at least 12 cores 
resulted in an overall diagnostic yield for prostate cancer of 
10.8%–26.2% [12,13], which is in line with the 22.8% yield in 
our study. Currently, despite several efforts to improve the 
detection rate of prostate cancer, there exists a challenging 
cohort of patients with substantial risk for prostate cancer 
who had a first negative biopsy.
 Fluctuating serum PSA levels is a common clinical situa-
tion encountered in daily practice. Earlier studies have evalu-
ated the clinical significance of PSA fluctuation after initial 
the patients and was locally advanced in only 9.4%. No signif-
icant differences in pathologic outcomes were found among 
patients according to the PSA fluctuation pattern.
DISCUSSION
When a patient presents with an initial negative prostate biop-
sy, a repeat biopsy should be performed because of persistent 
clinical suspicions of prostate cancer, such as abnormal DRE 
findings, increasing PSA level, and pathologic findings at ini-
tial biopsy. The number of positive prostate biopsies decreases 
with repeat biopsy (34% for the first prostate biopsy, 25% for 
the second, 24% for the third, and 21% for the fourth and fol-
Table 2. Univariate and multivariate logistic regression analysis predicting the presence of prostate cancer at repeated TRUS-Bx
Factor
Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Age 1.045 1.001–1.076 0.042 1.026 0.934–1.055 0.125
PSA 1.159 1.035–1.287 0.035 1.089 0.893–1.238 0.094
Prostate volume 0.945 0.607–1.455 0.381 - - -
Transition zone volume 0.927 0.709–1.224 0.401 - - -
PSA fluctuating pattern
Group 1 3.012 1.704–5.322 <0.001 3.151 1.771–5.608 <0.001
Group 2 2.941 1.725–5.015 <0.001 2.996 1.747–5.139 <0.001
Group 3 Reference Reference
Abnormal DRE findings 1.605 0.783–3.049 0.426 - - -
HGPIN at initial TRUS-Bx 2.163 1.508–4.896 0.002 2.019 1.439–4.323 0.004
ASAP at initial TRUS-Bx 1.209 0.793–2.128 0.411 - - -
TRUS-Bx, transrectal ultrasound guided prostate biopsy; OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen; DRE, digital rectal ex-
amination; HGPIN, high grade prostatic intraepithelial neoplasia; ASAP, atypical small acinar proliferation of prostate.
Table 3. Pathologic characteristics of the 96 patients who underwent radical prostatectomy after diagnosis of prostate cancer at re-
peated TRUS-Bx
Overall (n=96) Group 1 (n=44) Group 2 (n=31) Group 3 (n=21) P-value
T stage 0.859
pT2a 17 (17.7) 7 (15.9) 6 (19.4) 4 (19.0)
pT2b 1 (1.0) 0 (0) 1 (3.2) 0 (0)
pT2c 69 (71.9) 32 (72.7) 21 (67.7) 16 (76.2)
pT3a 8 (8.3) 4 (9.1) 3 (9.7) 1 (4.8)
pT3b 1 (1.0) 1 (2.3) 0 (0) 0 (0)
N stage 0.463
N0 38 (39.6) 19 (43.2) 13 (41.9) 6 (28.6)
N1 1 (1.0) 0 (0) 1 (3.2) 0 (0)
Nx 57 (59.4) 25 (56.8) 17 (54.8) 15 (71.4)
Gleason score 0.784
≤6 56 (58.3) 25 (56.8) 17 (54.8) 14 (66.7)
7 36 (37.5) 17 (38.6) 12 (38.7) 7 (33.3)
≥8 4 (4.2) 2 (4.5) 2 (6.5) 0 (0)
Tumor volume, mean (range) 8.9 (1–25) 9.2 (1–25) 9.5 (1–20) 7.7 (1–20) 0.177
Positive surgical margin 14 (14.6) 7 (15.9) 5 (16.1) 2 (9.5) 0.758
Values are presented as number (%) unless otherwise indicated.
TRUS-Bx, transrectal ultrasound guided prostate biopsy.
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negative prostate biopsy [6,14]. Celhay et al. [6] analyzed the 
cancer detection rate of repeat prostate biopsy according to 
fluctuating PSA levels. The percentage of prostate cancer was 
lower in the fluctuating PSA group than in the group with 
steady or steadily increasing PSA, but the difference was not 
significant (21.5% vs. 32.1%, P = 0.14). Similarly, Taverna et 
al. [14] reported that there were no significant differences 
between patients with fluctuating PSA and steadily increas-
ing PSA in terms of prostate cancer detection, or clinical or 
pathological stage. These findings are not consistent with 
those of our study. In our study, PSA fluctuation pattern was 
a significant predictive parameter for positive repeat biopsy. 
However, the number of patients in these prior studies was 
limited, and the results may be statistically underrepresented. 
Furthermore, fluctuating PSA level in their study was defined 
as a PSA series with at least one PSA value lower than the one 
immediately preceding it. Under such a definition only, the 
effect of biological variations in PSA may be underestimated. 
Therefore, it is important to understand the biological and 
analytical variations that constitute a significant change in 
serum PSA.
 PSA variation, even when PSA is measured in the same lab-
oratory, is now well established. Roehrborn et al. [15] identi-
fied patients who underwent two serum PSA measurements 
within less than 90 days, with the first PSA being less than 
10 ng/mL. They reported that only 6% of their patients had 
the same PSA value on both occasions; 55% had decreased 
PSA levels and 40% had increased PSA levels at the second 
sampling. Nixon et al. [16] reported that the median critical 
change ensuring a statistically significant difference between 
two PSA measurements was 20.5% and that an increase of 
45.8% in PSA concentration would need to be observed to 
be certain that an increase in PSA was statistically significant 
for 95% of men. Boddy et al. [17] analyzed the intraindividual 
variability of PSA by obtaining four PSA values over 4 weeks 
in 64 men with benign prostate biopsies. The median coef-
ficient of PSA variation was 9.5%, and there was a clear linear 
relationship between the mean PSA level and the standard 
deviation. The results indicated that patients who cause the 
most clinical concern because of their higher PSA are also 
those who have the most variation in PSA. Thus, analyzing 
the risk of prostate cancer using PSA fluctuation alone might 
be a clear indication of a methodological problem.
 In the current study, we classified the patients with PSA 
fluctuation according to the PSAV: PSA fluctuation with 
PSAV≥1.0 ng/mL/yr and PSA fluctuation with PSAV<1.0 ng/
mL/yr. Several authors have reported that PSAV is an indepen-
dent predictor of prostate cancer. Carter et al. [18] suggest a 
cutoff value of 0.75 ng/mL/yr for PSAV for identification of men 
with prostate cancer or benign prostatic disease with a PSA 
level greater than 4 ng/mL. The recent study by Ulmert et al. 
[19] analyzed data from the Malmö Preventive Medicine study 
to justify the significance of using PSAV alone compared with 
PSA and PSAV in detecting prostate cancer in clinical practice. 
They found that PSAV had a strong association with a subse-
quent diagnosis of prostate cancer on univariate and multi-
variate analysis (area under the curve [AUC], 0.771). Using the 
PSAV risk count proposed by Carter et al. [20], Loeb et al. [21] 
demonstrated that after adjusting for PSA level and age, men 
with two serial PSAV measurements of >0.4 ng/mL/yr (risk 
count 2) had an 8.2-fold increase in the risk of prostate cancer 
compared with those with a risk count of ≤1. In our study, we 
found that patients with PSA fluctuation and PSAV ≥1.0 ng/
mL/yr had a 2.996-fold increase in the risk of prostate cancer 
by adopting the concept of PSAV for analyzing the clinical sig-
nificance of PSA fluctuation pattern.
 The current study has several limitations. First, although we 
tried to control factors that might have influenced the results 
by using multivariate analysis, ours is a retrospective study in 
a single institution. Although there is less chance of missing 
a cancer after at least two sets of biopsies are performed [22], 
we do not know how many cancers were missed in our TRUS-
Bx protocol. Finally, we did not analyze the PSA fluctuation 
pattern in patients who did not undergo repeat TRUS-Bx as a 
control. Physicians tended to perform repeat biopsy less fre-
quently for patients with PSA fluctuation; however, we cannot 
be certain that patients who did not undergo repeat biopsy 
did not have prostate cancer.
 In conclusion, the current study shows that the risk of pros-
tate cancer at repeat TRUS-Bx was higher in men with a fluc-
tuating PSA level and PSAV ≥1.0 ng/mL/yr than in those with 
a fluctuating PSA level and PSAV <1.0 ng/mL/yr. Further stud-
ies are required to determine the detailed clinical relevance of 
these findings in order to reduce the number of unnecessary 
biopsies.
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